Blue Trust’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Blue Trust's CRSP Position: Q3 2026 in Review
Blue Trust opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 2 shares worth $93. The stake represents ﹤0.01% of the portfolio and ranks #2430 among its holdings. This is a return to the name: Blue Trust previously reported a position in CRSP as recently as Q1 2026.
Blue Trust first reported a position in CRSP in Q3 2022 and has held it in 14 quarters since. The position peaked at $208K in Q3 2024. 423 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Blue Trust held 2 shares of CRISPR Therapeutics worth $93 as of Q3 2026.
- CRISPR Therapeutics was a new Blue Trust position in Q3 2026.
- CRISPR Therapeutics made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #2430 holding.
- Blue Trust first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 14 quarters since.
- Blue Trust's CRISPR Therapeutics position peaked at $208K in Q3 2024.
- 423 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.